

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Hypertension

**ESPS manuscript NO:** 14279

**Title:** The Symplicity-3 Hypertension Trial: Basic and Clinical Insights

**Reviewer's code:** 00225357

**Reviewer's country:** Italy

**Science editor:** Fang-Fang Ji

**Date sent for review:** 2014-09-28 19:35

**Date reviewed:** 2014-12-01 17:52

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	PubMed Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input checked="" type="checkbox"/> Rejection
<input checked="" type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

## COMMENTS TO AUTHORS

In this review Authors try to explain the reasons why HTN-Simplicity 3 trial di not work. Authors state that the lack of a biomarker able to show the efficacy of the procedure is the main flaw of the trial. Authors' hypothesis is unconvincing since a sham group is the best way to show if a procedure is effective. Simplicity-3 is a methodologically sound trial with immaculate data. Authors should focus their criticism on procedure deployed in the clinical practice well before the demonstration of their efficacy and without passing the health technology assessment.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Hypertension

**ESPS manuscript NO:** 14279

**Title:** The Symplicity-3 Hypertension Trial: Basic and Clinical Insights

**Reviewer's code:** 00608153

**Reviewer's country:** China

**Science editor:** Fang-Fang Ji

**Date sent for review:** 2014-09-28 19:35

**Date reviewed:** 2014-12-11 15:32

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	PubMed Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

## COMMENTS TO AUTHORS

This is an interesting article. However, several confounding factors that include variations in the denervation procedure, changes in patient medications, and differences in drug adherence may have impacted trial results. Therefore, all these confounding factors should be considered in the design of future renal denervation. The subgroup analysis might be necessary to explain the results of renal denervation. These confounding factors should be mentioned in this review. Furthermore, at least two articles published in Hypertension after Symplicity-3 might be helpful to revise this article.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Hypertension

**ESPS manuscript NO:** 14279

**Title:** The Symplicity-3 Hypertension Trial: Basic and Clinical Insights

**Reviewer's code:** 02890067

**Reviewer's country:** Croatia

**Science editor:** Fang-Fang Ji

**Date sent for review:** 2014-09-28 19:35

**Date reviewed:** 2014-12-03 07:45

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	PubMed Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

## COMMENTS TO AUTHORS

This is an interesting paper which may improve our knowledge in the fields. The subject matter is suitable for the intended audience and it fits the journal scope. Article is mostly clearly written, but Title is suggestive of the article's content. Article is appropriately organized and the headings are indicative of content I suggest to accept this paper in the present form.